Chemotherapy with etoposide and cisplatin or carboplatin
|
|
- Sylvia Norris
- 5 years ago
- Views:
Transcription
1 Brief Report A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Shun Lu, MD,* Lu Li, MD, Yi Luo, MD, Li Zhang, MD, Gang Wu, MD, Zhiwei Chen, MD,* Cheng Huang, MD, Shuliang Guo, MD,# Yiping Zhang, MD,** Xiangqun Song, MD, Yongfeng Yu, MD,* Caicun Zhou, MD, Wei Li, MD, Meilin Liao, MD,* Baolan Li, MD, Liyan Xu, MD, Ping Chen, MD, Chunhong Hu, MD, and Chengping Hu, MD## Background: Based on promising efficacy in a single-arm study, a randomized phase II trial was designed to compare the efficacy and safety of adding rh-endostatin (Endostar) to first-line standard etoposide and carboplatin (EC) chemotherapy for treatment of extensivestage small-cell lung cancer. Methods: One hundred forty Chinese patients with pathologically confirmed, extensive-stage small-cell lung cancer were randomly assigned to EC alone or rh-endostatin + EC for 4 6 cycles, followed by single-agent rh-endostatin until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, Objective response rate (ORR), and quality of life. *Department of Oncology, Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China; Department of Thoracic Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Department of Medical Oncology, Hunan Provincial Tumor Hospital, Changsha, Hunan, China; Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China; The Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fujian Medical University Educational Hospital, Fuzhou, China; #Department of Respiratory Medicine, The First Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing, China; **Chemotherapy Center of Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Department of Chemotherapy, Affiliated Tumor Hospital, Guangxi Medical University, Guangxi, China; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China; Cancer Center of the First University Hospital, Jilin University, Changchun, China; Department of General, Beijing Chest Hospital, Beijing, China; Department of Oncology, Second Xiangya Hospital of Central-South University, Changsha, China; and ##Department of Respiratory Disease, Xiang-ya Hospital, Central Southern University, Hunan, Changsha, China. Disclosure: The authors declare no conflict of interest. Address for correspondence: Shun Lu, MD, Department of Oncology, Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiaotong University, 241 West Huaihai Road, Xuhui District, Shanghai , China. lushun1964@126.com DOI: /JTO ISSN: /15/ Results: Median PFS was 6.4 months with rh-endostatin + EC and 5.9 months with EC (hazard ratio 0.8 [95% confidence interval ]). PFS was significantly higher with rhendostatin + EC than with EC (hazard ratio 0.4 [ ; p = 0.020]) in female. Median overall survival was similar in both groups (12.1 versus 12.4 months, respectively [p = 0.82]). ORR was higher in the rh-endostatin + EC group (75.4%) than in the EC group (66.7%) (p = 0.348). The efficacy of rh-endostatin + EC relative to that of EC was reflected by greater improvements in patient-assessed quality of life scores after 4 and 6 weeks of treatment. There was no difference between each regimen in the incidence of nonhematological or Grade III IV hematological toxicities. Conclusions: Addition of rh-endostatin to EC for the treatment of extensive-stage small-cell lung cancer had an acceptable toxicity profile, but did not improve overall survival, PFS, and ORR. Key Words: Etoposide, Carboplatin, Rh-endostatin, Extensive-stage small-cell lung cancer, Survival. (J Thorac Oncol. 2015;10: ) Chemotherapy with etoposide and cisplatin or carboplatin has been the standard treatment for small-cell lung cancer (SCLC) over the last 30 years. These regimens are associated with response rates of 50 60% with a very short median progression-free survival (PFS) of 2 6 months and median survival times of 7 11 months. 1,2 Rh-endostatin (Endostar) is a novel recombinant human endostatin, and was approved for non SCLC (NSCLC) in China in It has been shown to improve overall survival (OS) and PFS when combined with first line chemotherapy in patients with advanced NSCLC. 3,4 A single-arm phase II study of cisplatin/ etoposide plus Rh-endostatin in 33 patients with extensivestage SCLC reported a median PFS of 5 months, median OS of 11.5 months, and objective response rate (ORR) of 69.7%. 5 This study aimed to assess the efficacy and safety of rh-endostatin in combination with first-line standard chemotherapy of etoposide plus carboplatin in the treatment of extensivestage SCLC. 206 Journal of Thoracic Oncology Volume 10, Number 1, January 2015
2 Journal of Thoracic Oncology Volume 10, Number 1, January 2015 Extensive-Stage Small-Cell Lung Cancer MATERIAL AND METHODS Patients and Eligibility This study enrolled 140 patients with histologically or cytologically confirmed extensive-stage, treatment-naive SCLC at 14 medical institutions in China between July 2009 and Aug All patients were between 18 and 75 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 and expected survival of more than 12 weeks. Other inclusion/exclusion/withdrawal criteria were standard for phase II studies (see Supplemental Digital Content, com/jto/a700). Details on informed consent, ethical clearance, and trial registration are also provided in the Supplemental Digital Content ( Study Design Patients were randomly assigned to the following two treatment groups: etoposide and carboplatin (EC) group, and EC + rh-endostatin group. The EC + rh-endostatin group received a 3- to 4-hour intravenous infusion of rhendostatin (7.5 mg/m 2 once daily, equivalent to U/ m 2 of human endostatin; Shandong Simcere-Medgenn Bio- Pharmaceutical Co., Ltd., Yantai, China) on Days 1 to 14 of each 21-day cycle. Etoposide was administered (60 mg/m 2, Qilu Pharmaceutical Co., Ltd., Jinan, China) on days 1 to 5, and carboplatin (Bristol-Myers Squibb S.r.I., Sermoneta, Italy) was administered at a target area under the concentration curve of 5 mg/ml/min on day 1 of each cycle. All patients received four to six 21-day cycles. After four to six cycles, patients who did not display disease progression continued to receive rh-endostatin (7.5 mg/m 2 once daily) on days 1 to 14 of each 21-day cycle until tumor progression, unacceptable toxicity, discontinuation from study, or death. Patients allocated to the EC group received etoposide (60 mg/m 2 ) on days 1 to 5 and carboplatin at an area under the concentration curve of 5 mg/ml/min on day 1 of each cycle. Study Endpoints The primary study endpoint was assessment of PFS. The secondary endpoints included OS, ORR (sum of complete and partial remission rates), and quality of life (QOL). Tumors were assessed as per RECIST 1.0. Response to treatment was assessed every two cycles by computed tomography and confirmed at 21 days after treatment termination. All endpoints were assessed by an independent review committee that included experienced and trained medical and oncological professionals. Statistical Considerations Data are presented as numbers and percentages, medians and ranges, or means and standard deviations (±SD). Intergroup comparisons were performed using Student s t test, Wilcoxon rank-sum test, and Fisher s exact test, as appropriate. Efficacy data are presented for the intent-to-treat patient population. Survival was censored at the last tumor assessment. Median PFS and OS were estimated by Kaplan Meier methodology, and they are reported with 95% confidence intervals. Logrank test was used for comparison. A Cox proportional hazards model stratified by ECOG performance status (0 1 versus 2) and gender (male versus female) was used to obtain a point estimate of hazard ratio (HR) for rh-endostatin plus chemotherapy compared with chemotherapy alone. The per protocol analysis included all patients who received all drugs as per study protocol, and who did not use any forbidden drugs, did not deviate from study protocol, completed all assessments and did not withdraw from the study, except because of death. All analyses were conducted using SAS 9.0 (SAS Institute, Cary, NC). All probability tests were two-tailed, and p values less than 0.05 were considered statistically significant. RESULTS Subjects Characteristics Of the 140 patients enrolled, 2 withdrew consent after randomization; 69 patients were in the rh-endostatin + EC group, and 69 patients were in the EC control group. The study flow chart is shown in Figure 1. Table 1 depicts the baseline characteristics of enrolled patients. Efficacy Progression-free survival Follow-up analysis of patients by August 31, 2012, revealed disease progression or death in 58 patients (84.1%) receiving rh-endostatin + EC and in 56 patients (81.2%) receiving EC alone. Median PFS was 6.4 months for the rhendostatin + EC group, and 5.9 months for the EC group (p = 0.213). PFS at 6 months was 59.3% in the rh-endostatin + EC group and 46.6% in the EC group (Fig. 2). Subgroup analysis showed that PFS in female patients (n = 25) was significantly higher with rh-endostatin + EC (7.3 months) compared with EC alone (3.9 months) (p = 0.020). The corresponding HR in female patients was 0.4 ( ) (Fig. 3). Objective remission rate The corresponding ORR (95% confidence interval) was 75.4% ( %) with rh-endostatin + EC and 66.7% ( %) with EC, but the difference was not statistically significant (p = 0.348). However, analysis of the per-protocol population showed that the ORR was significantly higher in patients treated with rh-endostatin + EC (86.7%; range: %) than in the EC group (71.0%; range: %; p = 0.046) (Table 2). Overall survival Median OS among patients receiving rh-endostatin + EC (12.1 months) was similar to that among patients receiving EC alone (12.4 months; p = 0.812). The 1-year survival rate was 50.0% with rh-endostatin + EC and 54.6% with EC. The corresponding HR (95% confidence interval) was 1.0 ( ). Similar results were obtained in the per-protocol population (HR: 1.0 [ ]) (Fig. 4). Lung cancer symptom scale QOL scores Improvements in patient-assessed QOL were significantly greater after 4 and 6 weeks of treatment with rh-endostatin + EC compared with EC (Fig. 5). 207
3 Lu et al. Journal of Thoracic Oncology Volume 10, Number 1, January 2015 Figure 1. Study flowchart and patient disposition. EC, etoposide and carboplatin; ITT, intention-to-treat. Safety The most common non-hematological adverse events (AEs) in both groups included nausea, anorexia, elevated alanine aminotransferase levels, elevated aspartate aminotransferase levels, vomiting, and weakness (Table 3). In the rh-endostatin + EC group, one patient had elevated blood pressure, another had nodal tachycardia and atrial premature beats, and another reported palpitation. These events were all mild in intensity and were not reported in the EC group. II study comparing rh-endostatin + first-line EC chemotherapy with EC chemotherapy alone in patients with advanced stage SCLC. The median PFS with rh-endostatin + EC was observed to be slightly longer than with EC alone, but without DISCUSSION Rh-endostatin has been shown to have clinical activity against NSCLC. 3,4 This study reports the findings of a phase Table 1. Baseline Characteristics Characteristics rh-endostatin + EC p Value Age (years) Mean (SD) 57.7 (8.49) 58.2 (7.84) Median (range) 56.0 (40 76) 59.0 (36 73) Gender Male 56 (81.2%) 57 (82.6%) Female 13 (18.8%) 12 (17.4%) ECOG 0 12 (17.4%) 13 (18.8%) (75.4%) 55 (79.7%) 2 5 (7.2%) 1 (1.4%) ECOG, Eastern Cooperative Oncology Group. Figure 2. Progression-free survival (PFS) curve. EC, etoposide and carboplatin. 208
4 Journal of Thoracic Oncology Volume 10, Number 1, January 2015 Extensive-Stage Small-Cell Lung Cancer Figure 3. Subgroup analysis of progression-free survival curve. EC, etoposide and carboplatin; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; CI, confidence interval. significant difference. The results were similar to those of other studies of bevacizumab, paclitaxel, or irinotecan in combination with rh-endostatin. 6 9 In as unplanned subgroup analysis, data suggest that Rh-endostatin + EC resulted in a significant PFS benefit over EC chemotherapy alone among female patients with SCLC. This is an interesting finding, since it is generally recognized that the incidence of lung cancer is increasing among female patients, 10 but further studies are necessary to confirm this finding. Nevertheless, it has also been reported that female gender is a good prognostic factor for extensive-stage SCLC, and that women with both NSCLC and SCLC survive longer than men. 10,11 In this study, there was no significant difference in OS in patients allocated to rh-endostatin + EC and those receiving EC alone. These survival rates were comparable to those observed with EC + bevacizumab or paclitaxel or irinotecan. 1,6 9 The negative results observed in this study were comparable to the results from studies of rh-endostatin + EC in patients with advanced SCLC, 5,12 and to the results of adding rh-endostatin to paclitaxel and carboplatin in NSCLC. 13 Promising results were obtained using sunitinib maintenance therapy, 14 and the right choice of drug combination might be essential to obtain positive results from rh-endostatin. The difference of ORR between the two groups was not statistically significant, while another study showed an improved ORR in patients receiving rh-endostatin. 12 However, when considering the per-protocol population only, ORR was significantly higher with rh-endostatin + EC (86.7%) than with EC (71.0%; p = 0.046). Nevertheless, when considering the whole population or the per protocol population, ORR achieved with rh-endostatin + EC was higher than that reported for EC + bevacizumab or irinotecan, and was comparable to Table 2. Remission Rates Category rh-endostatin + EC Number of Patients p Value Complete remission 2 (2.9%) 1 (1.4%) Partial remission 50 (72.5%) 45 (65.2%) Stable disease 5 (7.2%) 12 (17.4%) Progressive disease 3 (4.3%) 6 (8.7%) No assessment 9 (13.0%) 5 (7.2%) Objective response rate 75.4% ( %) 66.7% ( %) a a Fisher s exact test. Objective response rate is the sum of the complete and partial remission rates. Figure 4. Overall survival (OS) curve. EC, etoposide and carboplatin. 209
5 Lu et al. Journal of Thoracic Oncology Volume 10, Number 1, January 2015 Figure 5. Lung cancer symptom score quality of life assessments. Data are expressed as median. *p < EC, etoposide and carboplatin; QOL, quality of life. that reported for EC + irinotecan. 1,6 9 Randomized studies should be performed to directly compare these drugs with rh-endostatin. The efficacy of rh-endostatin + EC relative to that of EC alone was reflected by greater improvements in patientassessed lung cancer symptom scale QOL scores after 4 and 6 weeks of treatment. This finding is in line with a previous study showing improved QOL with rh-endostatin plus carboplatin in the early stages of treatment of advanced NSCLC. 13 The tolerability of rh-endostatin + EC was comparable to that reported in another phase II study. 5 No cases of severe cardiovascular toxicity were reported, and there were no hematological AEs. However, improvements in QOL alone, without improvements in OS or PFS, are not sufficient to adopt a new treatment. The better QOL observed in this study might be the result of more frequent visits to the hospital for the patients receiving rh-endostatin on a daily basis. However, the impact Table 3. Incidence of Adverse Reactions All Grades, N (%) Grades III to V, N (%) Adverse Reaction Rh-endostatin + EC p Value Rh-endostatin + EC ( = 69) p Value Hematopoietic system Leukopenia 62 (89.9%) 63 (91.3%) (29.0%) 15 (21.7%) Neutropenia 61 (88.4%) 56 (81.2%) (55.1%) 27 (39.1%) Hemoglobin 55 (79.7%) 53 (76.8%) (15.9%) 7 (10.1%) Thrombocytopenia 36 (52.2%) 34 (49.3%) (18.8%) 13 (18.8%) Anemia 10 (14.5%) 4 (5.8%) (1.4%) 2 (2.9%) Decreased absolute lymphocytes 2 (2.9%) 3 (4.3%) (1.4%) 1 (1.5%) Decreased lymphocyte counts 0 (0%) 3 (4.3%) (0%) 1 (1.5%) Myelosuppression 1 (1.4%) 0 (0%) (1.4%) 0 (0%) Digestive system Nausea 21 (30.4%) 20 (29.0%) (1.4%) 0 (0%) Anorexia 18 (26.1%) 13 (18.8%) (1.4%) 0 (0%) Aminopherase 16 (23.2%) 12 (17.4%) (0%) 1 (1.5%) Vomiting 9 (13.0%) 10 (14.5%) (1.4%) 0 (0%) Constipation 3 (4.3%) 1 (1.4%) (0%) 0 (0%) N/A Hyperbilirubinemia 3 (4.3%) 1 (1.4%) (0%) 0 (0%) N/A Diarrhea 1 (1.4%) 1 (1.4%) (1.4%) 1 (1.5%) Abdominal distension 2 (2.9%) 0 (0%) (1.4%) 0 (0%) Fecal occult blood 1 (1.4%) 0 (0%) (0%) 0 (0%) N/A General disorders Weakness 6 (8.7%) 5 (7.2%) (2.9%) 0 (0%) Alopecia 6 (8.7%) 4 (5.8%) (0%) 0 (0%) N/A Fever 1 (1.4%) 1 (1.4%) (0%) 0 (0%) N/A Infection 1 (1.4%) 0 (0%) (0%) 0 (0%) N/A Agranulocytic fever 1 (1.4%) 0 (0%) (0%) 0 (0%) N/A Laboratory abnormalities LDH 1 (1.4%) 2 (2.9%) (0%) 0 (0%) N/A Hypocalcemia 1 (1.4%) 0 (0%) (0%) 0 (0%) N/A Electrolyte disturbance 1 (1.4%) 0 (0%) (0%) 0 (0%) N/A LDH, lactate dehydrogenase; N/A, not applicable. 210
6 Journal of Thoracic Oncology Volume 10, Number 1, January 2015 Extensive-Stage Small-Cell Lung Cancer of the 3- to 4-hour daily infusions for 14 consecutive days might counteract this benefit. Despite the relatively long median follow-up of 20 months among patients with advanced stage SCLC, the relatively small sample size may have limited the power of the study to detect statistically significant differences between treatment regimens. In addition, the patients were selected from 14 different centers across China. While this strategy may make the study more applicable to a real-life setting, differences in patient procedures between the centers may have influenced the study endpoints. Finally, tumor markers were not measured. CONCLUSIONS The preliminary findings in a small population of patients with advanced SCLC suggest that the addition of rhendostatin to EC for the treatment of extensive-stage SCLC had an acceptable toxicity profile, but did not improve OS, PFS, or ORR. Hence, the use of rh-endostatin in SCLC remains exploratory. ACKNOWLEDGMENTS The authors thank the physicians, nurses, pathologists, and laboratory technicians who were involved in this study. The authors also appreciate the participation of all the patients and their families for their support. This work was supported by grants from Simcere Pharmaceutical Co., China, International S&T Cooperation Program of China (2012DFG31320), Foundation for Leaders of Disciplines in Science of Shanghai (13XD ), Science and Technology Commission Foundation of Shanghai (06DZ19501), and National High Technology Research and Development Program of China (2012AA02A502). REFERENCES 1. Noda K, Nishiwaki Y, Kawahara M, et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346: Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8: Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005;8: Rong B, Yang S, Li W, et al. Systematic review and meta-analysis of Rh-endostatin (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 2012;10: Zhou ZT, Zhou FX, Wei Q, et al. Phase II study of cisplatin/etoposide and rh-endostatin for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 2011;68: Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27: Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29: Niell HB, Herndon JE 2nd, Miller AA, et al; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial J Clin Oncol 2005;23: Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27: Svensson G, Ewers SB, Ohlsson O, Olsson H. Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. Clin Respir J 2013;7: Kuo YH, Lin ZZ, Yang YY, et al. Survival of patients with small cell lung carcinoma in Taiwan. Oncology 2012;82: Chen JH, Luo YZ, Zhou WW, et al. Recombinant human endostatin combined carboplatin plus etoposide for advanced small-cell lung cancer ASCO Annual Meeting. 2014:e Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with rh-endostatin for advanced non-small cell lung cancer. J Thorac Oncol 2011;6: Ready N, Pang H, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: a randomized, placebo controlled phase II study CALGB (ALLIANCE) ASCO Annual Meeting. 2013:
Cancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationPostoperative survival for patients with thymoma complicating myasthenia gravis preliminary retrospective results of the ChART database
Original Article Postoperative survival for patients with thymoma complicating myasthenia gravis preliminary retrospective results of the ChART database Fangrui Wang 1, Liewen Pang 1, Jianhua Fu 2, Yi
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationIrinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a metaanalysis
Xu et al. BMC Cancer (2018) 18:808 https://doi.org/10.1186/s12885-018-4715-9 RESEARCH ARTICLE Open Access Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationOncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small
More informationPlatinum-based doublet chemotherapy is the standard firstline
ORIGINAL ARTICLE A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel, MD,* John D. Hainsworth, MD,*
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationIntroduction ORIGINAL ARTICLE. Yuankai Shi 1,YiHu 2, Xingsheng Hu 1, Xue Li 3, Lin Lin 1 & Xiaohong Han 1
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
More informationLung cancer remains the leading cause of cancer-related
ORIGINAL ARTICLE Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer Cancer and Leukemia Group B Study 39901 Stephen L. Graziano, MD,* James E. Herndon, II, PhD, Mark
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationEffect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus
Original papers Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus Hongyang Lu 1,2,A,B,D, Fajun Xie 2,B, Zhiyu Huang 2,B, Jing Qin 2,C,E, Na Han
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThe efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationAfatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC
Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC Vera Hirsh, 1 Eng-Huat Tan, 2 Yi-Long Wu, 3 Lecia V. Sequist, 4 Caicun Zhou,
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationLarge-cell neuroendocrine carcinoma (LCNEC) and
BRIEF REPORT Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung A Multicenter Phase II Study Seiji Niho, MD, PhD,* Hirotsugu Kenmotsu, MD, Ikuo Sekine,
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)
Consensus Page 1 of 5 China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version) Yuankai Shi 1, Yan Sun 1, Cuimin Ding 2, Ziping Wang 1, Changli Wang 3, Zheng Wang 4, Chong
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationXu et al. Journal of Hematology & Oncology (2017) 10:22 DOI /s
Xu et al. Journal of Hematology & Oncology (2017) 10:22 DOI 10.1186/s13045-016-0384-9 RESEARCH Open Access Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationHanrui Chen, Xuewu Huang, Shutang Wang, Xinting Zheng, Jietao Lin, Peng Li, Lizhu Lin
Original Article Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial Hanrui Chen,
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationBackground 1. Comparative effectiveness of nintedanib
NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Shi et al. Journal of Hematology & Oncology (2017) 10:69 DOI 10.1186/s13045-017-0439-6 LETTER TO THE EDITOR Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationOverview. Author Summary: Abstract and Brief Discussion
Overview First Published Online October 1, 2014 DOI: 10.1634/theoncologist.2014-0223 Title: S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationPORCINE SPLEEN PEPTIDES HAVE BEEN TESTED AND USED EXTENSIVELY IN CHINA. BELOW ARE SUMMARIES OF TWENTY-EIGHT CLINICAL STUDIES
PORCINE SPLEEN PEPTIDES HAVE BEEN TESTED AND USED EXTENSIVELY IN CHINA. BELOW ARE SUMMARIES OF TWENTY-EIGHT CLINICAL STUDIES Study Title Location Number Effect of Pain Relief of Patients with Advanced
More informationPhase IV clinical trial of Shufeng Jiedu Capsule in the treatment of cases of acute upper espiratory infection of wind-heat syndrome
tp tp Phase IV clinical trial of Shufeng Jiedu Capsule in the treatment of 2 031 cases of acute upper espiratory infection of wind-heat syndrome XU Yan-ling 1, ZHANG Hui-hong 2, XUE Yun-li 2, YANG Jing-sheng
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSupplementary Information
Supplementary Information Prognostic Impact of Signet Ring Cell Type in Node Negative Gastric Cancer Pengfei Kong1,4,Ruiyan Wu1,Chenlu Yang1,3,Jianjun Liu1,2,Shangxiang Chen1,2, Xuechao Liu1,2, Minting
More informationSystemic chemotherapy improves both survival and quality
ORIGINAL ARTICLE Treatment of Elderly Non small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Suresh Ramalingam,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More information